HR Execs on the Move

Elevar Therapeutics

www.elevartherapeutics.com

 
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Josh Stearn
 Sr. Director, Marketing Profile
Heather Lane
 Associate Director, Supply Chain Profile
Jenny Gizzi
 Chief People Officer Profile

Similar Companies

United Pharma

United Pharma is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GFS Chemicals

GFS Chemicals is a Powell, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Smiles Dental

Welcome to Smiles Dental! Were proud to offer One of a Kind(ness) dentistry at our convenient offices across Washington and Oregon.

Dompé

Dompé: un impegno costante nella ricerca scientifica per lo sviluppo di farmaci innovativi per migliorare lo stato di salute dell’uomo

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.